This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

About Zinforo

About Zinforo

OverviewExtended spectrum coverage
Dosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosing
Efficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric Safety
Clinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE study
Support & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® provides dosing options to treat paediatric patients from birth1Dosage in paediatric patients with normal renal function (CrCL > 50 mL/min*¶)​​​​​​​
Scroll left to view table
Age and bodyweight Dosage Frequency Infusion time (minutes)
Neonates from birth to <2 months 6 mg/kg Every 8 hours 60
2 months to <2 years 8 mg/kg Every 8 hours 5-60†‡
2 years to <12 years 12 mg/kg up to 400 mg Every 8 hours 5-60†‡
12 years to <18 years and bodyweight <33 kg 12 mg/kg up to 400 mg Every 8 hours 5-60†‡
12 years to <18 years and bodyweight ≥33 kg 600 mg Every 12 hours 5-60†‡

A high-dose regimen is also available for paediatric patients aged ≥2 months with cSSTI confirmed or suspected to be caused by S. aureus with an MIC = 2 mg/L or 4 mg/L to Zinforo (refer to dosing tables within the SmPC for more detailed information).

Zinforo can be used in patients with varying degrees of renal impairment1Dosage in children aged from 2 years to <12 years with CrCL ≤50 mL/min and adolescents aged from 12 to <18 years with bodyweight <33 kg and CrCL ≤50 mL/min

For high dose regimen recommendations for patients with renal impairment, refer to dosing tables within the SmPC.

Explore More Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI1-4​​** Learn more Loading

*Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73 m2). 1
¶Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.1
†Infusion times of <60 minutes, neonatal and high-dose recommendations are based on PK/PD analyses only.1 
‡ Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis).1 Infusion times of <60 minutes are based on PK/PD analyses only.1
** Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.

Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CrCL, creatinine clearance; MIC, minimum inhibitory concentration.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References

ZINFORO. Summary of Product CharacteristicsLaudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18 Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7 Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0222. September 2021
Discover further specific information on the use of Zinforo in neonates, infants and children here: Zinforo provides simple dosing and a flexible infusion time for the majority of adult and adolescent patients1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​